BeiGene
BGNE
#881
Rank
HK$178.75 B
Marketcap
HK$1,597
Share price
-0.65%
Change (1 day)
2.73%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of June 2024 : HK$18.23 Billion

According to BeiGene 's latest financial reports the company's total liabilities are HK$18.23 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2024)

Total liabilities by year

Year Total liabilities Change
2023-12-31HK$17.71 B13.58%
2022-12-31HK$15.59 B-16.77%
2021-12-31HK$18.73 B39.59%
2020-12-31HK$13.42 B171.88%
2019-12-31HK$4.93 B27.1%
2018-12-31HK$3.88 B37.25%
2017-12-31HK$2.83 B589.86%
2016-12-31HK$0.41 B24.71%
2015-12-31HK$0.32 B52.28%
2014-12-31HK$0.21 B-44.86%
2013-12-31HK$0.39 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
HK$94.5 M-99.48%๐Ÿ‡บ๐Ÿ‡ธ USA
HK$4.54 B-75.08%๐Ÿ‡บ๐Ÿ‡ธ USA